Efficacy of Erbium Laser Therapy in Treating Vaginal Relaxation Syndrome

Background on Vaginal Relaxation Syndrome and Treatment Options

Vaginal Relaxation Syndrome (VRS) is a condition that affects many women, particularly following childbirth or as they age. This syndrome can lead to a range of symptoms including decreased vaginal elasticity, reduced sexual satisfaction, and urinary incontinence. The physiological changes associated with VRS can significantly impair a woman’s quality of life, affecting not just her physical health but also her emotional and psychological well-being.

Traditional treatment options for VRS have included hormonal therapies, particularly estrogen, to restore vaginal health. However, these methods often come with a range of side effects and may not be suitable for all patients. As a result, there is an increasing interest in non-invasive treatment options that can provide effective relief without the drawbacks associated with hormonal therapy.

One such innovative approach is the use of Erbium laser therapy, which utilizes a specific wavelength of light to stimulate collagen remodeling in the vaginal tissues. This technique has been proposed as a potential solution for improving vaginal health indicators such as elasticity, lubrication, and overall sexual function.

Methodology of the Retrospective Study on Laser Therapy

The efficacy of Erbium laser therapy was evaluated through a retrospective study conducted at the China-Japan Friendship Hospital. The study included two groups of women diagnosed with VRS—one group receiving Erbium laser therapy (n = 130) and a control group undergoing estrogen treatment (n = 112).

Data were collected on various parameters including demographic characteristics, clinical outcomes, vaginal microenvironment indicators, and sexual function. The primary outcomes assessed included changes in pelvic floor muscle strength, vaginal atrophy scores, vaginal pH levels, lactobacilli grades, and sexual satisfaction levels as measured by validated questionnaires.

Table 1: Demographic and Clinical Characteristics of Participants

Key Outcomes: Impact of Laser Therapy on Vaginal Health Indicators

At the three-month follow-up, the results indicated significant improvements in the laser therapy group compared to the estrogen group. Specifically, the laser group exhibited remarkable enhancements in pelvic floor muscle strength (P = 0.046) and reductions in vaginal atrophy scores (P = 0.035).

Additionally, the patients receiving Erbium laser therapy reported higher levels of sexual satisfaction, particularly in terms of increased orgasm frequency (P = 0.007). While both groups demonstrated improvements in lactobacilli grades and vaginal pH, these changes were not statistically significant (both P > 0.05), indicating that while laser therapy had a positive impact, the microenvironmental changes were less pronounced.

Table 2: Changes in Vaginal Health Indicators

Comparison of Laser Therapy and Estrogen Treatment for VRS

The comparison between the two treatment modalities reveals that while both Erbium laser therapy and estrogen treatment can enhance vaginal health, the laser therapy presents a non-invasive alternative that may offer additional benefits in terms of patient satisfaction and functionality.

Furthermore, the lower incidence of adverse reactions in the Erbium laser therapy group (P < 0.05) suggests that this method could be preferable for women seeking effective treatment without the systemic effects associated with hormone therapy.

Conclusion: The Role of Transvaginal Erbium Laser Therapy in Enhancing Sexual Health

In conclusion, transvaginal Erbium laser therapy has emerged as a promising intervention for alleviating symptoms of Vaginal Relaxation Syndrome. The significant improvements in pelvic floor muscle strength, reduced vaginal atrophy, and enhanced sexual satisfaction underscore the potential of this treatment modality.

Further research is warranted to establish long-term outcomes and to compare the efficacy of laser therapy with other emerging non-invasive treatments in the context of women’s sexual health.

Frequently Asked Questions (FAQ)

What is Vaginal Relaxation Syndrome (VRS)?

VRS is a condition characterized by a loss of vaginal elasticity and muscle strength, typically associated with childbirth and aging, leading to symptoms such as urinary incontinence and decreased sexual satisfaction.

How does Erbium laser therapy work?

Erbium laser therapy works by delivering focused laser energy to the vaginal tissues, stimulating collagen production, enhancing elasticity, and improving the overall health of the vaginal microenvironment.

Are there any side effects of Erbium laser therapy?

Most patients experience mild side effects, such as temporary discomfort or swelling. The incidence of adverse reactions is lower compared to hormone therapies.

How long does it take to see results from Erbium laser therapy?

Many patients report improvements within three months following treatment, particularly in terms of pelvic floor strength and sexual satisfaction.

Is Erbium laser therapy safe for all women?

While generally safe, women should consult their healthcare provider to determine if this treatment is suitable for their specific circumstances, including medical history and existing health conditions.

References

1. Elsharkawy, A. E., Lange, B., Caldas, F., Alabbasi, A. H., & Klassen, P. D. (2018). Predictors and Long-term Outcome of Sexual Function After Surgical Treatment for Single-level Lumbar Disk Herniation Among Patients in a German Spine Center. Clin Spine Surg, 31(8), 356–62

2. Korse, N. S., Veldman, A. B., Peul, W. C., & Vleggeert-Lankamp, C. L. A. (2017). The long term outcome of micturition, defecation and sexual function after spinal surgery for cauda equina syndrome. PLoS ONE, 12(4), e0175987. https://doi.org/10.1371/journal.pone.0175987

3. Panneerselvam, K., Kanna, R. M., Shetty, A. P., & Rajasekaran, S. (2022). Impact of Acute Lumbar Disk Herniation on Sexual Function in Male Patients. Asian Spine J, 16(4), 510–8. https://doi.org/10.31616/asj.2021.0083

4. Sahin, C. U., Aydin, M., Kalkisim, S., Sahin, H., & Arslan, F. C. (2022). Comparison of Preoperative and Postoperative Sexual Dysfunction in Male Patients with Lumbar Disc Herniation. Turk Neurosurg, 32(3), 442–8

5. Moradi, Z., Shahali, S., Ahmadi, F., & Montazeri, A. (2025). The implications of surgery on sexual dysfunction in patients with lumbar disc herniation with cauda equina syndrome: a systematic review. BMC Musculoskelet Disord, 24(1), 724. https://doi.org/10.1186/s12891-025-08736-3

6. Degirmentepe, R. B., Bozkurt, M., & Erkoc, M. (2025). The effect of video-animated information on the anxiety of male patients before flexible cystoscopy performed under local anesthesia. Can Urol Assoc J, 11(1), E189–E194

7. Yin, T., He, Y., & Huifang, C. (2025). Association between cardiometabolic index and postmenopausal stress urinary incontinence: a cross-sectional study from NHANES 2013 to 2018. Lipids Health Dis, 14, 1. https://doi.org/10.1186/s12944-025-02601-x

8. Giliberti, A., Giustiniano, S., Carbonaro, Y., Frisina, A. M., Roccella, M., & Serra, G. (2025). A new association between Kleefstra syndrome and Panayiotopoulos epilepsy. Ital J Pediatr, 94, 1. https://doi.org/10.1186/s13052-025-01982-0

9. Muacevic, A., Adler, J. R., Panganiban, E. L. C., & Rosales, R. L. (2025). Multiple System Atrophy (Cerebellar Type) With Overlapping Progressive Muscular Atrophy Features and Genetic Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4) Amyotrophic Lateral Sclerosis Variant: A Case Report. Cureus, 12(1), e82509. https://doi.org/10.7759/cureus.82509

10. Palermo, M., Trevisi, G., Signorelli, F., Doglietto, F., Albanese, A., & Olivi, A. (2025). Advancing treatment strategies for idiopathic normal pressure hydrocephalus: a systematic review on studies comparing ventricular and lumbo-peritoneal shunts. Neurosurg Rev, 36(2), 1-16. https://doi.org/10.1007/s10143-025-03582-2